(secondQuint)Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of MOF on Patients After Open Surgery for a RAAA.

 This trial is multicentre, randomised, double-blinded, Phase II, parallel group comparison study of the efficacy and safety of FP-1201-lyo compared to placebo in patients surviving emergency open surgery for an infra-renal ruptured abdominal aortic aneurysm.

 Investigational medicinal product will be administered as post-surgical preventive treatment either 10 mu g FP-1201-lyo or placebo.

 Treatment will be administered daily every 24 hrs for 6 days.

 The first dose will be given after successful surgery at the point when the patient arrives to the Intensive Care Unit (ICU).

 Both treatment groups will receive standard supportive care.

 Aim is randomise and initiate treatment of 152 patients.

 For the final analysis, a minimum of 129 evaluable patients will be required.

.

 Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of MOF on Patients After Open Surgery for a RAAA@highlight

A study to assess effectiveness and safety of a drug FP-1201-lyo (Recombinant Human Interferon Beta-1a) in the Prevention of Multi-Organ Failure on patients after Open Surgery for a Ruptured Abdominal Aortic Aneurysm